Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21772494 | 1.00 | L3MBTL1 (0.35) | L3MBTL1CTSLCTSBHTT | |
| SCHEMBL21772496 | 1.00 | L3MBTL1 (0.35) | L3MBTL1CTSLCTSBHTT | |
| SCHEMBL6064485 | 0.93 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL19924782 | 0.93 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL7417089 | 0.93 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL22750552 | 0.85 | CAPN1 (0.45) | CTSL | |
| SCHEMBL22750553 | 0.85 | CAPN1 (0.45) | CTSL | |
| SCHEMBL22750551 | 0.85 | CAPN1 (0.45) | CTSL | |
| SCHEMBL30914037 | 0.81 | CTSL (0.37) | CTSLCTSB | |
| SCHEMBL30396756 | 0.81 | CTSL (0.37) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2022265577-A2 | CORONAVIRUS ENZYME MODULATORS, METHODS OF SYNTHESIS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-22 | — | — | WO | disclosed |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | EMORY UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210395300-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | UNIV EMORY (US) | 2021-12-23 | — | — | US | disclosed |
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| WO-2020247665-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3455205-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | Emory University (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017197377-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | VIP, HAVCR2, NGLY1 | L3MBTL1 355/4885CTSL 280/4885CTSB 583/4885 |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | VIP, HAVCR2, NGLY1 | L3MBTL1 355/4885CTSL 280/4885CTSB 583/4885 |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | L3MBTL1 600/4885CTSL 88/4885CTSB 764/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | L3MBTL1 355/4885CTSL 280/4885CTSB 583/4885 |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | ACE2, SARS1, VIP | L3MBTL1 600/4885CTSL 88/4885CTSB 764/4885 |
| US-20210395300-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | L3MBTL1 355/4885CTSL 280/4885CTSB 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.